AstraZeneca shares in tentative rebound

AstraZeneca, the pharmaceutical giant, posted 3Q core EPS fell 4% on year to 0.94 dollar on revenue of 6.58 billion dollars, up 3% (+3% at constant exchange rate), above expectations.

Uptrend 2

AstraZeneca, the pharmaceutical giant, posted 3Q core EPS fell 4% on year to 0.94 dollar on revenue of 6.58 billion dollars, up 3% (+3% at constant exchange rate), above expectations. The company said "total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage". 

The U.K. drug agency has begun evaluating the future vaccine developed by AstraZeneca and Oxford University. AstraZeneca is expected to publish the results of much-anticipated advanced clinical trials in the coming weeks

From a chartist point of view, the stock price is reversing up thanks to the upside breakout of a former downward-sloping channel. The bullish gap opened yesterday above the 50DMA is a positive signal. In addition, the daily RSI (14) has broken above a key declining trend line. Readers may want to consider the potential for opening Long positions above the support at 7963p with 8848p and 9650p as targets. Only a break below 7963p would invalidate the bullish bias.

Source: GAIN Capital, TradingView


More from Epidemic

Disclaimer

This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.